Fibrobiologics Inc (FBLG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -8,062 | -7,562 | -8,460 | -16,485 | -6,768 |
| Depreciation Amortization | 420 | 277 | 137 | 518 | 388 |
| Accounts payable and accrued liabilities | N/A | N/A | -141 | 141 | 141 |
| Other Working Capital | 838 | 882 | 419 | 493 | 175 |
| Other Operating Activity | -2,024 | 181 | 3,770 | 8,932 | 1,264 |
| Operating Cash Flow | $-8,828 | $-6,222 | $-4,275 | $-6,401 | $-4,800 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -85 | -74 | -8 | -495 | -493 |
| Investing Cash Flow | $-85 | $-74 | $-8 | $-495 | $-493 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 574 | 574 | 574 | N/A | 0 |
| Common Stock Issued | 7,462 | 2,819 | 2,819 | N/A | N/A |
| Other Financing Activity | -459 | -287 | -115 | 13,793 | 13,793 |
| Financing Cash Flow | $7,577 | $3,106 | $3,278 | $13,793 | $13,793 |
| Beginning Cash Position | 9,163 | 9,163 | 9,163 | 2,266 | 2,266 |
| End Cash Position | 7,827 | 5,973 | 8,158 | 9,163 | 10,766 |
| Net Cash Flow | $-1,336 | $-3,190 | $-1,005 | $6,897 | $8,500 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,828 | -6,222 | -4,275 | -6,401 | -4,800 |
| Capital Expenditure | -85 | -74 | -8 | -495 | -493 |
| Free Cash Flow | -8,913 | -6,296 | -4,283 | -6,896 | -5,293 |